Ken Griffin Day One Biopharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 26,100 shares of DAWN stock, worth $373,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,100
Previous 15,300
70.59%
Holding current value
$373,752
Previous $252,000
42.46%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DAWN
# of Institutions
167Shares Held
71.7MCall Options Held
163KPut Options Held
183K-
Ra Capital Management, L.P. Boston, MA7.87MShares$113 Million1.63% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$92.1 Million11.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$66.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$64.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.78MShares$54.2 Million0.02% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.05B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...